Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Non Operating Income (2016 - 2025)

Guided Therapeutics' Non Operating Income history spans 11 years, with the latest figure at -$257000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 176.34% year-over-year to -$257000.0; the TTM value through Sep 2025 reached -$324000.0, down 1196.0%, while the annual FY2024 figure was -$309000.0, 865.62% down from the prior year.
  • Non Operating Income for Q3 2025 was -$257000.0 at Guided Therapeutics, down from $64000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $555000.0 in Q3 2021 and bottomed at -$560000.0 in Q2 2021.
  • The 5-year median for Non Operating Income is -$26000.0 (2023), against an average of -$9052.6.
  • The largest annual shift saw Non Operating Income skyrocketed 3288.89% in 2022 before it crashed 2800.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$9000.0 in 2021, then surged by 3288.89% to $287000.0 in 2022, then tumbled by 65.51% to $99000.0 in 2023, then crashed by 219.19% to -$118000.0 in 2024, then plummeted by 117.8% to -$257000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Non Operating Income are -$257000.0 (Q3 2025), $64000.0 (Q2 2025), and -$13000.0 (Q1 2025).